Evidence map›Paper›PMID 29332123›Full record

ArticleInvestigative ophthalmology & visual science2018

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.

Jasmine H Francis, Hans E Grossniklaus, Larissa A Habib, Brian Marr, David H Abramson, Klaus J Busam

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jasmine H FrancisOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Hans E GrossniklausDepartment of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, United States.
Larissa A HabibOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Brian MarrOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
David H AbramsonOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Klaus J BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Memorial Sloan Kettering Cancer Center · USCornell University · USEmory University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Purpose: To evaluate BRAF, NRAS, and GNAQ mutations in surgical specimens of common and blue conjunctival melanocytic nevi. Methods: Surgical specimens from 25 conjunctival melanocytic nevi (23 common and 2 blue) of 25 patients were evaluated. All common nevi were analyzed immunohistochemically for the expression of BRAF V600E or NRAS Q61R. One lesion with negative immunoreactivity and for all blue nevi, a hybridization capture-based next-generation sequencing method was employed for mutation analysis. For common nevi, genetic features were compared with clinical and histopathologic findings. Continuous variables (age at excision and largest basal diameter) were compared with a Students's t-test and all categoric variables were compared with Fisher's Exact Test. Results: Of common melanocytic nevi, 9 (39.1%) were immunoreactive for NRASQ61R and 13 (56.5%) were immunoreactive for BRAFV600E. One common nevus, which was immunonegative for both BRAFV600E and NRASQ61R was found to harbor an NRASQ61K mutation by sequence analysis. Patients with NRAS-mutated nevi were more likely to report occurrence of the lesion prior to 18-years old and more likely to have intrinsic cysts. The mean largest basal diameter was 6.0 and 3.5 mm for NRAS- and BRAF-immunoreactive lesions, respectively (P = 0.003). GNAQ mutations were identified in each of the two blue nevi of this study. Conclusions: These findings document that common conjunctival melanocytic nevi have mutually exclusive mutations in BRAF and NRAS. The two conjunctival blue nevi harbored GNAQ mutations. This suggests the driver mutations of conjunctival nevi are similar to those of nevi of the skin. At the molecular level, conjunctival nevi appear more like cutaneous nevi than choroidal nevi.

Indexed as

ConjunctivaMutationAdolescentAdultDNA Mutational AnalysisDNA, NeoplasmFemaleGTP-Binding Protein alpha Subunits, Gq-G11GTP PhosphohydrolasesHumansImmunohistochemistryMaleMembrane ProteinsNevus, PigmentedProto-Oncogene Proteins B-rafSkin NeoplasmsBRAF protein, humanDNA, NeoplasmGNAQ protein, humanGTP-Binding Protein alpha Subunits, Gq-G11GTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID29332123
PMCPMC6110167
OpenAlexW2783013315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.